Navigation Links
Leica Biosystems and Synthon Biopharmaceuticals Partner to Develop a Companion Diagnostic Program for Targeted Cancer Therapies
Date:3/12/2013

NEWCASTLE-UPON-TYNE, England, March 12, 2013 /PRNewswire/ --

  • Leica Biosystems and Synthon Biopharmaceuticals announce partnership to develop a companion diagnostic test for solid tumors
  • Leica Biosystems will develop a fully automated tissue-based companion diagnostic test to run on the BOND™ automated advanced staining systems
  • Synthon strengthens its innovative drug pipeline with the development of a companion diagnostic test
  • This agreement provides framework for further collaboration projects

Leica Biosystems and Synthon Biopharmaceuticals, a subsidiary of specialty pharma company Synthon, today announced an agreement to collaborate on the development and commercialization of a companion diagnostic test using the Leica BOND system, paired with one of Synthon Biopharmaceutical's antibody-drug conjugates (ADCs), to enhance the treatment of solid tumors.

"We are pleased to be working with Synthon Biopharmaceuticals on cancer therapies with the Leica BOND platform," added Matthias Weber , President of Leica Biosystems, MD.  "This partnership with Synthon is the next example of our commitment to provide unique tests to support the management of cancer patients. The ease of use and high staining quality of our BOND systems makes them ideal platforms on which to deploy these very informative tests."

Dr. Leon Hooftman , Chief Medical Officer at Synthon, comments: "Synthon is committed to develop a best-in-class ADC. This collaboration with Leica Biosystems will support us in delivering on that ambition."

About Leica Biosystems

Leica Biosystems is a global leader in workflow solutions and automation, striving to advance cancer diagnostics to improve patients' lives. Leica Biosystems provides anatomical pathology laboratories and researchers a comprehensive product range for each step in the pathology process, from sample preparation and staining to imaging and reporting. Leica's work program will be led from their new Companion Diagnostics Research and Development site in Danvers, Greater Boston, Massachusetts, with kit manufacturing occurring in Newcastle. Leica's easy-to-use and consistently reliable offerings help improve workflow efficiency and diagnostic confidence. The company is represented in over 100 countries. It has manufacturing facilities in 6 countries, sales and service organizations in 19 countries, and an international network of dealers. The company is headquartered in Nussloch, Germany. Further information can be found at http://www.LeicaBiosystems.com

About Synthon

Synthon, with headquarters in Nijmegen, the Netherlands is an international pharmaceutical company and a leader in the field of generic medicines. Synthon has been working in biotechnology since 2007 and is developing rapidly into a specialty pharmaceutical company, focusing on the therapeutic areas of auto-immune diseases - particularly multiple sclerosis - and oncology. Our products are currently approved by regulatory agencies in over 80 countries worldwide and marketed through strategic partnerships and - in dedicated areas - through direct sales. Synthon employs about 1,400 staff worldwide, and in 2011 it recorded a turnover of EUR 260 million. For more information, go to http://www.synthon.com.  

http://www.LeicaBiosystems.com

 



'/>"/>
SOURCE Leica Biosystems
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Indigo Biosystems Among “Best Places to Work” in Indiana
2. Indigo Biosystems Nominated for Two TechPoint Mira Awards for Technology Excellence and Innovation
3. Genesis Biosystems Unveils Innovative Skin Treatment at Esthétique SPA International Trade Show
4. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
5. Aushon BioSystems and AH diagnostics unterzeichnen Distributionsvertrag für Skandinavien
6. Aushon BioSystems and AH diagnostics Sign Distribution Deal for Scandinavia
7. AyoxxA Biosystems Closes Series A Financing Round
8. Aushon BioSystems Appoints Martin Verhoef Chief Executive Officer
9. Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series
10. Keryx Biopharmaceuticals to Present at the 15th Annual BIO CEO & Investor Conference Presentation Scheduled for Monday, February 11th at 2:30 PM ET
11. Gallus BioPharmaceuticals Announces Appointment of Senior Baxter Executive as Chief Commercial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... MA (PRWEB) , ... December 02, 2016 , ... Robots ... Light Event on December 3rd, 2016. The event, which is held on the ... work with helping Americans with Disabilities back into the workplace. Suitable Technologies is partnering ...
(Date:12/2/2016)... December 2, 2016 The immunohistochemistry (IHC) ... at a CAGR of 7.3% during the forecast period of 2016 ... diagnostic laboratories segment accounted for the largest share of immunohistochemistry (IHC) ... , ... global immunohistochemistry (IHC) market spread across 225 pages, profiling 10 companies ...
(Date:11/30/2016)... ... November 30, 2016 , ... BEI Kimco, a brand ... a flexure design that ensures high alignment accuracy by preventing unwanted shaft rotation. ... suited where extreme precision is required, such as in medical equipment, laboratory instrumentation, ...
(Date:11/30/2016)... , November 30, 2016 ... a few players hold a dominant share in the ... River Laboratories International, Inc., and Merck KGaA, held a ... 2015. Transparency Market Research observes that these companies are ... on development products that are do not require rabbit ...
Breaking Biology Technology:
(Date:11/19/2016)... , Nov. 18, 2016 Securus Technologies, ... solutions for public safety, investigation, corrections and monitoring, announced ... smaller competitor, ICSolutions, to have an independent technology judge ... the most modern high tech/sophisticated telephone calling platform, and ... customers that they do most of what we do ...
(Date:11/15/2016)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a ... gut microbiome, today announced the pricing of an ... common stock and warrants to purchase 50,000,000 shares ... the public of $1.00 per share and accompanying ... offering, excluding the proceeds, if any from the ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
Breaking Biology News(10 mins):